Pragmatic Randomized Clinical Trial — Effectiveness in Real-World Care
- Introduced by
- Daniel Schwartz & Joseph Lellouch
- Year
- 1967
- Type
- Interventional study design
- Family
- Clinical / epidemiology
What does it do?
A pragmatic randomized clinical trial (pragmatic RCT) is an interventional study that tests whether a treatment works under routine clinical conditions, as opposed to the tightly controlled setting of an explanatory trial. It prioritizes broad eligibility, flexible delivery, and patient-relevant outcomes to answer the question 'Does this treatment work in everyday practice?' rather than 'Can this treatment work under ideal circumstances?' The distinction between pragmatic and explanatory trials was formally articulated by Schwartz and Lellouch in 1967 and operationalized by the PRECIS tool in 2009.
The intuition behind the method
Think of the difference between testing a new drug in a specialty clinic with hand-picked patients who follow a strict protocol, versus testing that same drug across ordinary general practices with typical patients and usual clinical workflows. The first is an explanatory trial — it asks whether the drug can work. A pragmatic RCT asks whether it does work for real patients in real settings. By relaxing strict inclusion criteria, allowing clinicians to adjust doses as they normally would, and measuring outcomes that patients actually care about, a pragmatic RCT produces evidence that translates directly into clinical decisions and healthcare policy.
History
The explanatory versus pragmatic distinction was first formally articulated by French statisticians Daniel Schwartz and Joseph Lellouch in their 1967 paper in the Journal of Chronic Diseases. They observed that trials designed to test whether a treatment can work (explanatory) differ fundamentally in design logic from trials designed to inform clinical choice (pragmatic). The concept gained traction slowly, but grew in prominence during the 1990s and 2000s as health technology assessment bodies sought real-world evidence. In 2009, Thorpe and colleagues published the PRECIS (Pragmatic-Explanatory Continuum Indicator Summary) tool to help trialists make their pragmatic intent explicit; an updated PRECIS-2 tool followed in 2015.
When to use it
Use a pragmatic RCT when the intervention has already shown biological plausibility or efficacy in explanatory trials and the key question is whether it works under routine care conditions for a broad patient population. It is the design of choice for comparative effectiveness research, health technology assessment, and implementation research. It is particularly suited to behavioral interventions, complex health system interventions, or established drugs being compared head-to-head. Do not use a pragmatic RCT when you still need to establish mechanism of action, dose-finding, or safety under controlled conditions — those questions require explanatory or early-phase trials. Also avoid a fully pragmatic design when regulatory approval is the goal, as agencies typically require more controlled evidence.
Limitations and considerations
- Greater heterogeneity in delivery and patient population increases variance, requiring larger sample sizes to detect treatment effects.
- Flexible protocols and permitted co-interventions make it harder to isolate the active ingredient of the intervention.
- Routine care data sources may have missing values, inconsistent coding, or limited granularity compared to prospective data collection.
- Blinding is often impossible (especially for behavioral or complex interventions), introducing performance and detection bias.
- Results may still not generalize beyond the healthcare systems and settings included in the trial.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Produces effectiveness evidence directly applicable to clinical decision-making and policy because conditions mirror real-world practice.
- Broad inclusion criteria capture the diverse, comorbid patients actually treated in practice, improving external validity.
- Flexible delivery and usual-care comparators reduce protocol-driven effects that inflate efficacy estimates in explanatory trials.
- Outcomes are often collected via routine data sources, reducing cost and participant burden while enabling large sample sizes.
- Randomization preserves internal validity, giving pragmatic RCTs an advantage over observational effectiveness studies.
Applications
- Comparing two antihypertensive drug classes in unselected primary care patients to inform prescribing guidelines.
- Evaluating a nurse-led chronic disease management program across community health centers with routine electronic health records as the data source.
- Testing a behavioral weight-loss intervention delivered by primary care teams under usual-practice conditions.
- Assessing the comparative effectiveness of two surgical techniques in diverse hospital settings including teaching and non-teaching hospitals.
- Cluster-randomized trials testing quality improvement interventions at the level of the ward, clinic, or general practice.
How it works
How it works
Researchers position the trial on the explanatory-pragmatic continuum using a tool such as PRECIS-2, which rates twelve domains (eligibility, recruitment, setting, organization, flexibility in delivery, flexibility in adherence, follow-up, primary outcome, participant compliance, and practitioner adherence) from fully explanatory to fully pragmatic. The overall design goal is to reflect conditions as close to routine care as possible.
Eligibility criteria are kept broad to include the heterogeneous patient population actually seen in practice — including those with comorbidities, polypharmacy, or limited adherence. Recruitment typically occurs in multiple diverse settings (community clinics, hospitals, primary care) rather than specialized research centers.
Participants are randomly allocated to the intervention or comparator arm. The comparator is usually usual care or the current standard treatment rather than a placebo, because the relevant clinical question is comparative effectiveness. Cluster randomization (randomizing clinics or practices rather than individuals) is common to avoid contamination in real-world settings.
The intervention is implemented as it would be in routine practice: clinicians can exercise judgment about dosing adjustments, co-interventions are permitted, and protocol deviations are documented but not always penalized. This flexibility is what distinguishes pragmatic delivery from explanatory-trial protocols.
Outcomes are chosen for clinical and patient relevance — quality of life, hospital admissions, functional status, or mortality — rather than surrogate or mechanistic endpoints. Outcomes are often collected through routine health records, patient-reported outcome measures, or administrative databases to minimize research burden.
The primary analysis follows an intention-to-treat (ITT) principle — all randomized participants are analyzed in their assigned group regardless of adherence — because this reflects real-world effectiveness rather than idealized efficacy. Subgroup analyses may explore heterogeneity of treatment effects across patient types or settings.
Common pitfalls
- Ignoring the PRECIS-2 framework at design stage — failing to map out where each design element sits on the pragmatic-explanatory continuum leads to inconsistent choices that undermine both internal and external validity.
- Using a placebo comparator when usual care is the relevant alternative — this answers the wrong clinical question and overstates effectiveness relative to what patients will actually receive.
- Underpowering due to underestimated heterogeneity — the wider variability in pragmatic settings means power calculations based on explanatory-trial effect sizes are often optimistic; pilot data from real settings are essential.
- Reporting as if the trial were explanatory — pragmatic RCTs should be reported with explicit statement of pragmatic intent (CONSORT extension for pragmatic trials) and position on the PRECIS-2 wheel.
- Conflating pragmatic design with poor rigor — pragmatism refers to real-world applicability, not relaxed scientific standards; randomization, allocation concealment, and ITT analysis remain mandatory.
Frequently asked questions
What is the PRECIS-2 tool and should I use it?
PRECIS-2 (Pragmatic-Explanatory Continuum Indicator Summary, version 2) is a validated 9-domain rating wheel that helps trial designers characterize and communicate how pragmatic or explanatory each element of their trial design is. Domains include eligibility, recruitment, setting, organization, flexibility of the intervention and comparator, follow-up intensity, primary outcome, and analysis approach. Using PRECIS-2 at the design stage ensures that design choices are coherent with the trial's purpose and supports transparent reporting. Most journals publishing pragmatic trials now expect a PRECIS-2 diagram in the methods section.
Can I blind participants in a pragmatic RCT?
Blinding is often not feasible or not desirable in pragmatic trials — particularly for behavioral, surgical, or complex health system interventions — because the trial is designed to reflect routine care. When blinding is impossible, the risk of performance and detection bias should be acknowledged and outcome assessors should be blinded where possible. The absence of blinding does not disqualify a trial from being a legitimate pragmatic RCT, but it must be reported transparently.
How does a pragmatic RCT differ from a large simple trial?
These concepts overlap but are not identical. A large simple trial is characterized by a very large sample, minimal data collection beyond the primary outcome, and broad eligibility — all features consistent with pragmatism. A pragmatic RCT can be small if the setting and design choices reflect routine care. The pragmatic label refers to the philosophy of design (real-world applicability), whereas 'large simple trial' refers more to the operational strategy of maximizing sample size and minimizing complexity.
Is a pragmatic RCT suitable for regulatory submissions?
Generally, regulatory agencies such as the FDA and EMA require controlled, explanatory-style evidence for initial marketing approval because they need to establish efficacy and safety under defined conditions. However, pragmatic data are increasingly accepted for label extensions, post-marketing commitments, and health technology assessments. Some agencies have published guidance on real-world evidence, and pragmatic RCT data can complement — though rarely replace — explanatory trial packages for regulatory purposes.
What comparator should a pragmatic RCT use?
The appropriate comparator is the best available current treatment or usual care — whatever the patient would realistically receive if not enrolled in the trial. Using a placebo comparator in a pragmatic trial is usually inappropriate because it does not answer the comparative effectiveness question that clinicians and patients face. Head-to-head comparisons of active treatments are the norm, and the choice of comparator should be justified based on current clinical practice in the target setting.
Related methods
Sources
Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648.
Open DOI referenceCopied.Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... & Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology, 62(5), 464–475.
Open DOI referenceCopied.